Category: ADMA Biologics

ADMA Biologics Shares Possibly Worth A Triple On FDA Approval Of RI-002

We are initiating coverage of ADMA Biologics, Inc. (ADMA) with a “Buy” rating and a $20 price target. ADMA recently announced positive Phase 3 data for lead product candidate RI-002, a plasma-derived intravenous immunoglobulin (IVIG) for the treatment and prevention of certain infectious diseases in Primary Immunodeficiency Disease (PIDD) patients. RI-002 contains high levels of…